The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1689-1392
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice ; volume:23 ; number:1 ; day:15 ; month:12 ; year:2018 ; pages:1-11 ; date:12.2018
Cellular & molecular biology letters ; 23, Heft 1 (15.12.2018), 1-11, 12.2018
- Creator
-
Liang, Leilei
Ge, Keli
Zhang, Fengying
Ge, Yinlin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s11658-018-0122-0
- URN
-
urn:nbn:de:101:1-2019013123072454598025
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Liang, Leilei
- Ge, Keli
- Zhang, Fengying
- Ge, Yinlin
- SpringerLink (Online service)
Other Objects (12)
RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
rTMS improves dysphagia by inhibiting NLRP3 inflammasome activation and caspase-1 dependent pyroptosis in PD mice
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
rTMS improves dysphagia by inhibiting NLRP3 inflammasome activation and caspase-1 dependent pyroptosis in PD mice
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
rTMS improves dysphagia by inhibiting NLRP3 inflammasome activation and caspase-1 dependent pyroptosis in PD mice
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports